Field Trip, a leader in the development and delivery of psychedelic therapies, has announced the lead indications for FT-104, its novel psychedelic compound in development, will be Treatment Resistant Depression (TRD) and Postpartum Depression (PPD). Through Field Trip Discovery, its drug development division, Field Trip is developing next-generation psychedelic molecules. Its first molecule in development, FT-104, a prodrug, is a synthetic serotonin-2A…
![](https://femtechinsider.com/wp-content/uploads/2021/09/field-trip-amsterdam-1000x658.jpeg)